Business Wire

Western Union Expands Global Real-Time Payments Network

Share

Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement and payments, today announced continued expansion of its Global Network for real-time money-movement and payments, benefiting the Company’s consumers and clients across its branded money transfer and payments business as well as its expanding white-label business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200423005498/en/

Western Union’s vast global retail network of over 550,000 agent locations across more than 200 countries and territories has offered in-minutes payout for many decades. And now Western Union customers have the choice of moving funds globally with speed, with the company’s expanded capability to send cross-border, cross-currency money transfers and payments real-time to 50 countries when paid into select banks and digital wallets. The expansion has been fast-tracked since the beginning of this year with the goal of assessing as many as 100 countries for real-time capabilities by the end of 2020. Western Union’s global network now includes more than four billion bank account and wallets.

Western Union’s expansion of digital pay-in and pay-out, a strategic pillar for years, has become an especially critical capability as people around the world continue sending money to their loved ones and making business payments during the COVID-19 pandemic. During the crisis, Western Union has focused on accelerating the expansion of its digital money transfer capabilities so more consumers and business can make essential cross-border payments and transfers from the safety of their homes.

Last month, Western Union announced the expansion of its digital money transfer services, the fastest-growing part of its business in 2019, to more than 75 countries. The Company’s digital services capture all the top 20 of the world’s primary remittance-sending countries ranked by the World Bank. Similarly, the Company’s global bank account and wallet payout network, along with in-minutes payout capability to select bank accounts and wallets, covers most of the world’s major remittance-receiving countries. Given the critical nature of money movement during the COVID-19 crisis, this end-to-end coverage assures that these reliable, convenient digital services are available to millions of the world’s most active money movers.

“Western Union is continuing to execute on its strategy by investing in and growing our global network to empower businesses and consumers to move money or make payments how they choose, to where they choose, as quickly as possible,” said Western Union President and CEO Hikmet Ersek. “The COVID-19 crisis has strengthened our commitment to be a reliable partner for people and enterprises to move funds globally in real-time.”

Ersek said, “This is a prime example of how the expanding global reach, interconnectedness and speed of Western Union’s global network generates customer benefits that are difficult to match. Our unique platform cuts through international complexities so customers can access their funds in real-time in more and more places. As we expand from our roots in consumer remittances, we’re positioning ourselves as the platform of choice for next-generation payments businesses and financial institutions and their diverse cross-border payments needs.”

Western Union’s consumer-to-consumer money in-minutes cross-border payments capability is now active when sending to select banks or digital wallet providers in 50 countries: Austria, Bangladesh, Bulgaria, Burundi, Cambodia, Cameroon, China, Costa Rica, Cyprus, Czech Republic, Democratic Republic of Congo (DRC), Denmark, Estonia, Ethiopia, Fiji, Finland, France, Ghana, Guatemala, India, Indonesia, Italy, Ivory Coast, Kenya, Latvia, Lithuania, Luxembourg, Malawi, Mexico, Mongolia, Mozambique, Nepal, Netherlands, Nigeria, Pakistan, Philippines, Portugal, Rwanda, Senegal, Spain, Sri Lanka, Sweden, Switzerland, Tanzania, Turkey, Uganda, Ukraine, United Arab Emirates, Zambia and Zimbabwe.

Accelerating Access to Cross-Border Transfers In-Minutes

The advancement of Western Union’s global cross-border, cross-currency money movement platform – including international real-time cross-border transfers, global settlement capabilities, network, compliance and technology systems — is positioning the company as the world’s foremost integrator of money movement and payments, globalizing services for its own customers as well for financial institutions and other payment providers.

In addition to its expansive digital footprint and settlement and compliance infrastructure, Western Union boasts a global retail network with in-minutes payout to more than 550,000 agent locations across more than 200 countries and territories.

Western Union’s recently announced open-platform strategy is allowing the company to innovatively connect the digital and physical worlds of money while helping leading organizations scale their services globally. The company offers banks and other payment providers a portfolio of application programming interfaces (APIs) to integrate with its cross-border, cross-current money movement platform with the added benefit of Western Union’s treasury management, reconciliation, and global compliance capabilities.

WU-G

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of December 31, 2019, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.

Contact information

Media Contacts:
Western Union Global Communications
Pia De Lima; Pia.DeLima@westernunion.com
+1 (954) 260-5732

Western Union Americas
Margaret Fogarty; maragaret.fogarty@wu.com

Western Union Middle East & Africa
Mohamed El Khalouki; Mohamed.ElKhalouki@wu.com

Western Union Asia-Pacific
Karen Santos; Karen.Santos2@westernunion.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom